## Susan Tsai, MD, Appointed Director of Surgical Oncology at OSUCCC – James

Leading with Precision and Compassion in the Fight Against Gastrointestinal Cancers



**New York City, New York Oct 23, 2024 (**<u>Issuewire.com</u>**)** - Columbus, Ohio - The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) proudly announces the leadership of Dr. Susan Tsai, a distinguished surgical oncologist and appointed Director of the Division of Surgical Oncology. With an impressive career dedicated to enhancing care for patients battling gastrointestinal cancers, Dr. Tsai is

renowned for her expertise in pancreatic cancer and related diseases on an international scale.

Embodying a patient-centered approach, Dr. Tsai focuses on improving access to innovative and personalized treatment options for all patients. She is a staunch advocate for the implementation of precision medicine, aiming to tailor therapies to the unique genetic profiles of her patients. Moreover, Dr. Tsai encourages patient participation in clinical trials, believing that these opportunities foster hope and provide customized treatment plans that can lead to better outcomes.

In addition to her clinical responsibilities, Dr. Tsai is committed to advancing the future of cancer care through collaborative efforts with leading clinicians and researchers at The James. Her dedication to accelerating the translation of novel therapies into clinical practice is unwavering. She firmly believes that integrated partnerships with clinicians and translational researchers are essential for fueling discovery and innovation in cancer treatment.

As a pivotal member of the Translational Therapeutics Program at The James, Dr. Tsai is also recognized as a National Institutes of Health (NIH) funded researcher. Her research focuses on blood-based biomarkers and precision medicine clinical trials specifically for pancreatic cancer. Notably, she has spearheaded several investigator-initiated clinical trials that have pioneered the use of molecular profiling to guide chemotherapeutic selection in the neoadjuvant setting.

After completing medical school at the University of Michigan Medical School in Ann Arbor in 2001, Dr. Tsai pursued a residency in general surgery at Michigan Medicine. Building on this foundation, she advanced to a prestigious fellowship in complex general surgical oncology at Johns Hopkins Hospital in Baltimore. Dr. Tsai further refined her expertise with a graduate program at the Johns Hopkins Bloomberg School of Public Health and currently serves as a Professor of Surgery at The Ohio State University College of Medicine.

An accomplished author, Dr. Tsai has contributed over 130 peer-reviewed scientific articles and 17 book chapters to the field. She serves on the editorial board for the Journal of GI Surgery and Surgery and acts as an ad-hoc reviewer for respected publications such as BMC Cancer, JAMA Surgery, and Clinical Cancer Research.

With her extensive expertise and visionary leadership, Dr. Susan Tsai is poised to make significant strides in the realm of surgical oncology and cancer care at OSUCCC-James.

## Learn More about Dr. Susan Tsai:

Through her findatopdoc profile,

https://www.findatopdoc.com/doctor/81812529-Susan-Tsai-Surgical-Oncologist or through The Ohio State University, https://cancer.osu.edu/find-a-doctor/search-physician-directory/susan-tsai

## About FindaTopDoc.com

FindaTopDoc is a digital health information company that helps connect patients with local physicians and specialists who accept your insurance. Our goal is to help guide you on your journey towards optimal health by providing you with the know-how to make informed decisions for you and your family.

## **Media Contact**

Your Health Contact

clientservice@yourhealthcontact.com

Source: Susan Tsai, MD

See on IssueWire